The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.
Richard S. Finn
Research Funding - Eisai
Ann-Lii Cheng
Consultant or Advisory Role - Eisai
Kenji Ikeda
Honoraria - Bayer; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Eisai; Olympus Medical Systems
Expert Testimony - Eisai
Masatoshi Kudo
Honoraria - Bayer; Daiichi Sankyo; Eisai
Toshiyuki Tamai
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
Corina E. Dutcus
Employment or Leadership Position - Eisai
Steven Younger
Employment or Leadership Position - Eisai
Kwang-Hyub Han
Consultant or Advisory Role - Eisai
Research Funding - Clinical Trial Research Grant
Shukui Qin
No relevant relationships to disclose
Eric Raymond
Consultant or Advisory Role - Eisai